ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0661

Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial

Lisa Stamp1, Rebecca Grainger2, Chris Frampton1, Jill Drake1 and Catherine Hill3, 1University of Otago, Christchurch, Christchurch, New Zealand, 2University of Otago, Wellington, New Zealand, 3Queen Elizabeth Hospital, Woodville, Australia

Meeting: ACR Convergence 2021

Keywords: diet, gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), also known as omega-3 fats act as alternate COX substrates to arachidonic acid (AA). Their metabolism results in production of prostaglandins which are less inflammatory than those derived from AA. Thus omega-3 fatty acids can act as a “natural” anti-inflammatory drug. Regular use of anti-inflammatory doses of omega 3 fish oil may be particularly useful as a prophylaxis against gout flares during the introduction of urate lowering therapy, and acceptable to patients due to tolerability and lack of major adverse effects compared to other prophylactic medications. The aim of this study was determine the effect of omega-three supplementation with fish oil on serum urate (SU), weight and body mass index (BMI) in people with gout.

Methods: A pilot 6-month, randomized, open-label clinical trial was undertaken in people with gout with serum urate ≥6mg/dL/l. Forty participants were randomized to receive 6.2g omega-3 fish oil daily (manufactured by Melrose (Mt Waverley, Victoria, Australia)or no fish oil for 24 weeks. Blood was obtained monthly for SU and red cell EPA (20:5n-3) DHA (22:6n-3) were measured using a blood spot collection system. The primary efficacy outcome was the change in SU between baseline and week 24 (or the final visit for those who discontinued fish oil or were lost to follow-up). Secondary outcomes included (i) change in weight and BMI between baseline and week 24, (ii) mean number of flares per month between baseline and week 24, (iii) percentage of participants with flares at each month, (iv) cessation of fish oil therapy prior to week 24 due to adverse effects or intolerance and (v) change in oxypurinol, HBA1c, cholesterol, HDL, and LDL concentrations between baseline and week 24 for people on allopurinol.

Results: Five participants in the fish oil group discontinued the oil; three were unable to tolerate the taste, one commenced dabigatran and one found it inconvenient to take it. The baseline demographic and clinical features were well matched between randomized groups. There was no statistically significant difference in the mean (SEM) decrease in SU between baseline and week 24 between randomized groups: fish oil -0.021 (0.02) mmol/l vs. control -0.006 (0.02) mmol/l. There was no significant difference in change in weight or BMI between baseline and week 24 between randomized groups (Figure). There was a statistically significant correlation between red cell omega-three concentrations and the total number of flares per participant between week 12 and week 24; total omega-three r= -0.75 (p≤0.001), EPA r= -0.75 (p≤ 0.001) and DHA r= -0.76 (p≤ 0.001). In the omega-three fish oil group four participants reported gastrointestinal adverse effects definitely or probably related to the omega-three supplementation.

Conclusion: The lack of untoward effect of omega three fish oil supplementation on SU and BMI together with the relationship between higher omega-three concentrations and lower gout flares supports the development of further adequately powered clinical trials to determine the role of omega-three supplements as prophylaxis against gout flares in people starting urate lowering therapy.

Figure 1 A) Serum urate and B) percentage of participants with at least one flare in the preceding four weeks over the study period in controls and those receiving omega three fish oil.


Disclosures: L. Stamp, None; R. Grainger, Pfizer New Zealand, 6, 12, support to travel to conference, Jansenn Autralia, 6, 12, travel to symposia, AbbVie New Zealand, 6, Cornerstones, 6, novartis, 1; C. Frampton, None; J. Drake, None; C. Hill, None.

To cite this abstract in AMA style:

Stamp L, Grainger R, Frampton C, Drake J, Hill C. Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/effect-of-omega-three-supplementation-on-serum-urate-and-gout-flares-in-people-with-gout-a-pilot-randomized-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-omega-three-supplementation-on-serum-urate-and-gout-flares-in-people-with-gout-a-pilot-randomized-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology